Chief Science Officer, Public Health Agency of Canada (PHAC)
Dr. Rainer Engelhardt spoke about the following:
Overview of the history of Ebola outbreaks and how the current epidemic event is exceptional, but gives rise to concerns about future epidemics.
Leading vaccines under consideration for mass immunisation
The Canadian VSV Ebola vaccine – development, characteristics and mode of action, role of PHAC/NML
Licensing and commercialisation of the Canadian IP for the VSV vaccine to NewLink/BPS and Merck;
‘Carve-out rights’ for Canada; provision of VSV vaccine to WHO for emergency compassionate use
Clinical trial programme – Phase 1 and Phase 2 underway
Anticipated target markets – GAVI designated countries and anti-bioterrorism stockpiles
By Invitation: April 1, 2015
Centre Block, Parliament Hill
Building upon the impressive legacy of vaccines in Canada, the Health Research Caucus Luncheon on Vaccine Development in Canada will raise awareness among Parliamentarians about the fundamental approach to making vaccines, explain what they are and provide a history of vaccine development and the significant value, opportunities and challenges across the vaccine development chain in Canada
The Luncheon will also showcase PREVENT, a national Centre of Excellence for Commercialization and Research (CECR) focused on advancing Canada’s vaccine research and development by identifying promising vaccine technologies from Canadian academia and biotech and cultivating collaborative approaches to optimize their transition into attractive candidates for commercialization.
Finally, the event will profile the development of the experimental VSV-EBOV vaccine, developed by researchers at the Public Health Agency of Canada’s National Microbiology Laboratory (NML).